A new trading day began on Friday, with NovoCure Ltd (NASDAQ: NVCR) stock price up 4.78% from the previous day of trading, before settling in for the closing price of $19.26. NVCR’s price has ranged from $11.70 to $34.13 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.60% over the past five years. Meanwhile, its annual earnings per share averaged -27.01%. With a float of $98.88 million, this company’s outstanding shares have now reached $108.52 million.
Let’s look at the performance matrix of the company that is accounted for 1488 employees. In terms of profitability, gross margin is 77.33%, operating margin of -28.18%, and the pretax margin is -21.67%.
NovoCure Ltd (NVCR) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 10.04%, while institutional ownership is 83.64%. The most recent insider transaction that took place on Mar 03 ’25, was worth 5,071. In this transaction Chief Innovation Officer of this company sold 268 shares at a rate of $18.92, taking the stock ownership to the 166,243 shares. Before that another transaction happened on Mar 03 ’25, when Company’s EVP, Pres., Novocure Oncology sold 2,527 for $18.54, making the entire transaction worth $46,841. This insider now owns 143,673 shares in total.
NovoCure Ltd (NVCR) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.5 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.61% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Here are NovoCure Ltd’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -2.00 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
NovoCure Ltd (NASDAQ: NVCR) saw its 5-day average volume 1.15 million, a positive change from its year-to-date volume of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 46.78%. Additionally, its Average True Range was 1.23.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 28.06%, which indicates a significant decrease from 56.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.47% in the past 14 days, which was lower than the 89.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.71, while its 200-day Moving Average is $20.79. Nevertheless, the first resistance level for the watch stands at $20.70 in the near term. At $21.23, the stock is likely to face the second major resistance level. The third major resistance level sits at $21.95. If the price goes on to break the first support level at $19.45, it is likely to go to the next support level at $18.73. The third support level lies at $18.21 if the price breaches the second support level.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
With a market capitalization of 2.22 billion, the company has a total of 109,915K Shares Outstanding. Currently, annual sales are 605,220 K while annual income is -168,630 K. The company’s previous quarter sales were 161,270 K while its latest quarter income was -65,920 K.
